Alliance for Pandemic Preparedness

March 2, 2021

Evaluation of a SARS-CoV-2 Vaccine NVX-CoV2373 in Younger and Older Adults

Category:

Topic:

Keywords (Tags):

  • [Pre-print, not peer-reviewed] The two-dose Novavax recombinant nanoparticle vaccine candidate “NVX-CoV2373” induced robust IgG-anti-spike protein and neutralizing antibody titers against SARS-CoV-2 in both young and older participants, according to results from a Phase I/II trial (n=1,283). >98% of participants had seroconversion in both age groups fourteen days after the second dose. Reactogenicity was predominantly mild to moderate in severity and short in duration (median <3 days) after the first dose, with adverse events occurring in higher frequencies and intensities after the second dose among those receiving the 25-ug dose regimen.

Formica et al. (Mar 1, 2021). Evaluation of a SARS-CoV-2 Vaccine NVX-CoV2373 in Younger and Older Adults. Pre-print downloaded Mar 2 from https://doi.org/10.1101/2021.02.26.21252482